The humble Vitamin C has done it again!
Viral respiratory tract infections, such as the common cold, are the most prevalent illnesses to occur in humans - manifesting as a range of symptoms from rhinorrhoea, nasal congestion and sneezing to dry throat, coughing and headaches. Vitamin C is often the first supplement administered, and for good reason too.
Research shows that the immune-stimulatory properties of vitamin C aid in symptom alleviation as well as reduction in duration of the common cold.
Vitamin C levels decline swiftly at the onset of infection (presumably as it is used up by immune cells) but return to normal when symptoms have resolved.
Vitamin C is utilised by the immune system to enhance cell proliferation and function which lead to increased production of cytokines and antibodies. It can also destroy and prevent further production of histamine.
Vitamin C advantageously modulates lymphocytes and phagocytes, and regulates natural killer cells.
The success rate of vitamin C treatment for the common cold seems to depend on how much, and how often it is taken. Various clinical trials have been conducted with varying dosing patterns from 200mg to 8g daily, and, not surprisingly have produced inconsistent results. Some have demonstrated symptom relief, reduction in cold duration and reduced incidence, where others have failed.
For example, in a population group exposed to intense exercise and extreme cold, vitamin C reduced the incidence of colds by up to 50%, but this has not been shown in the wider population.
Braun and Cohen, 2010, recommend megadoses of vitamin C taken in frequent small amounts to achieve a daily dose beyond what has been clinically trialled. This dosing option appears, anecdotally, to give most positive results in practice, although interestingly has not received much research attention.
A reduction in both duration and severity of the common cold may be achieved if therapeutic doses of vitamin C are taken regularly at the onset of cold symptoms.